Clinical efficacy and safety: nervous system
The European Medicines Agency's scientific guidelines on the clinical evaluation of medicines used in nervous-system disorders help medicine developers prepare marketing authorisation applications for human medicines.
For a complete list of scientific guidelines currently open for consultation, see Public consultations.
Guidelines
- Clinical development of medicinal products for the treatment of autism spectrum disorder (ASD) - Scientific guideline
- Clinical development of medicinal products intended for the treatment of pain - Scientific guideline
- Clinical investigation of medicinal products for the treatment and prevention of bipolar disorder - Scientific guideline
- Clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis - Scientific guideline
- Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD) - Scientific guideline
- Clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy - Scientific guideline
- Clinical investigation of medicinal products for the treatment of multiple sclerosis - Scientific guideline
- Clinical investigation of medicinal products for the treatment of obsessive compulsive disorder - Scientific guideline
- Clinical investigation of medicinal products for treatment of migraine - Scientific guideline
- Clinical investigation of medicinal products in the treatment of depression - Scientific guideline
- Clinical investigation of medicinal products in the treatment of epileptic disorders - Scientific guideline
- Clinical investigation of medicinal products in the treatment of Parkinson's disease - Scientific guideline
- Clinical investigation of medicinal products indicated for generalised anxiety disorder - Scientific guideline
- Clinical investigation of medicinal products indicated for panic disorder - Scientific guideline
- Clinical investigation of medicinal products indicated for the treatment of social anxiety - Scientific guideline
- Clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia - Scientific guideline
- Development of medicinal products for the treatment of alcohol dependence - Scientific guideline
- Development of medicinal products for the treatment of post-traumatic stress disorder - Scientific guideline
- Development of new medicinal products for the treatment of smoking - Scientific guideline
- Clinical investigation of medicines for the treatment of Alzheimer's disease - Scientific guideline
- Medicinal products for the treatment of insomnia - Scientific guideline
- Treatment of premenstrual dysphoric disorder - Scientific guideline
Points to consider